Sees $4.5B of net cost savings by end of 2025. Expects additional productivity gains through 2027.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Options Volatility and Implied Earnings Moves Today, April 29, 2025
- Pfizer reports Q1 adjusted EPS 92c, consensus 68c
- Pfizer backs FY25 adjusted EPS view $2.80-$3.00, consensus $2.95
- Pfizer: Current guidance assumes no share repurchases in 2025
- Pfizer’s Financial Outlook: Hold Rating Amidst Short-Term Challenges and Long-Term Potential